FUNDC2 promotes liver tumorigenesis by inhibiting MFN1-mediated mitochondrial fusion
Li Shuaifeng, Han Shixun, Zhang Qi, Zhu Yibing, Zhang Haitao, Wang Junli, Zhao Yang, Zhao Jianhui, Su Lin, Li Li, Zhou Dawang, Ye Cunqi, Feng Xin-Hua, Liang Tingbo, Zhao Bin
Journal:Nature Communications
IF:17.69
DOI:10.1038/s41467-022-31187-6
PMID:35710796
Published:2022-06-17
research field:毒理学内分泌学环境卫生分子遗传学发育生物学
Abstract
Mitochondria generate ATP and play regulatory roles in various cellular activities. Cancer cells often exhibit fragmented mitochondria. However, the underlying mechanism remains elusive. Here we report that a mitochondrial protein FUN14 domain containing 2 ( FUNDC2 ) is transcriptionally upregulated in primary mouse liver tumors, and in approximately 40% of human hepatocellular carcinoma (HCC). Importantly, elevated FUNDC2 expression inversely correlates with patient survival, and its knockdown inhibits liver tumorigenesis in mice. Mechanistically, the amino-terminal region of FUNDC2 interacts with the GTPase domain of mitofusin 1 (MFN1), thus inhibits its activity in promoting fusion of outer mitochondrial membrane. As a result, loss of FUNDC2 leads to mitochondrial elongation, decreased mitochondrial respiration, and reprogrammed cellular metabolism. These results identified a mechanism of mitochondrial fragmentation in cancer through MFN1 inhibition by FUNDC2, and suggested FUNDC2 as a potential therapeutic target of HCC.
本文使用的Yeasen产品


